Session » RA – Animal Models Poster (1014–1021)

Date: Monday, November 8, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1016

Assessment of Pre-Inflammatory Mesenchymal (PRIME) Cells as a Biomarker of Tumor Necrosis Factor-Induced Arthritis in Mice

8:30AM-10:30AM: Abstract Number: 1019

Cigarette Smoking Induces Post-translational Protein Modifications in Both in Vitro and in Vivo Models of Rheumatoid Arthritis-associated Interstitial Lung Disease

8:30AM-10:30AM: Abstract Number: 1014

Enhanced Expression of Rheumatoid Arthritis Related Autoantibodies Following Airborne Endotoxin Exposure in the Setting of Collagen-Induced Arthritis

8:30AM-10:30AM: Abstract Number: 1020

Enhancing Endothelial Cell Barrier Function via Sphingosine -1 Phosphate Receptor 1 (S1PR1) – a Novel Treatment for Experimental Arthritis

8:30AM-10:30AM: Abstract Number: 1018

Joint-Draining Popliteal Lymphatic Vessels Exhibit Lymphatic Muscle Cell Dysfunction in TNF-Tg Mice with Inflammatory Arthritis

8:30AM-10:30AM: Abstract Number: 1021

Organic Dust Exposure Induces Post-translational Protein Modifications and a HLA-DR4-dependent Pro-inflammatory Lung Phenotype in a Murine Model of Interstitial Lung Disease

8:30AM-10:30AM: Abstract Number: 1017

Osteoclast-Specific Transmembrane Protein (OC-STAMP) Regulates Osteoclastogenesis and Inhibits Inflammation in an Acute Arthritis Model

8:30AM-10:30AM: Abstract Number: 1015

Preclinical Investigation of the First-in-Class SIK2/SIK3 Inhibitor GLPG3970 in Models of Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].